ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.